PuSH - Publication Server of Helmholtz Zentrum München: Impact of the selective A2<sub>A</sub>R and A2<sub>B</sub>R dual antagonist AB928/etrumadenant on CAR T cell function.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Seifert, M.* ; Benmebarek, M.R.* ; Briukhovetska, D.* ; Märkl, F.* ; Dörr, J.* ; Cadilha, B.L.* ; Jobst, J.* ; Stock, S.* ; Andreu-Sanz, D.* ; Lorenzini, T.* ; Grünmeier, R.* ; Oner, A.* ; Obeck, H.* ; Majed, L.* ; Dhoqina, D.* ; Feinendegen, M.* ; Gottschlich, A.* ; Zhang, J.* ; Schindler, U.* ; Endres, S.* ; Kobold, S.

Impact of the selective A2_AR and A2_BR dual antagonist AB928/etrumadenant on CAR T cell function.

Br. J. Cancer 127, 2175-2185 (2022)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Hybrid

Abstract
Metrics
Extra information

BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has been successfully translated to clinical practice for the treatment of B cell malignancies. The suppressive microenvironment of many malignancies is a bottleneck preventing treatment success of CAR T cells in a broader range of tumours. Among others, the immunosuppressive metabolite adenosine is present in high concentrations within many tumours and dampens anti-tumour function of immune cells and consequently therapeutic response. METHODS: Here, we present the impact of the selective adenosine A2_A and A2_B receptor antagonist AB928/etrumadenant on CAR T cell cytokine secretion, proliferation, and cytotoxicity. Using phosphorylation-specific flow cytometry, we evaluated the capability of AB928 to shield CAR T cells from adenosine-mediated signalling. The effect of orally administered AB928 on CAR T cells was assessed in a syngeneic mouse model of colon carcinoma. RESULTS: We found that immunosuppressive signalling in CAR T cells in response to adenosine was fully blocked by the small molecule inhibitor. AB928 treatment enhanced CAR T cell cytokine secretion and proliferation, granted efficient cytolysis of tumour cells in vitro and augmented CAR T cell activation in vivo. CONCLUSIONS: Together our results suggest that combination therapy with AB928 represents a promising approach to improve adoptive cell therapy.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Altmetric

9.075

0.000

PuSH - Publication Server of Helmholtz Zentrum München

Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function.

Impact of the selective A2_AR and A2_BR dual antagonist AB928/etrumadenant on CAR T cell function.